Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Filters
Results by year
Table representation of search results timeline featuring number of search results per year.
Year | Number of Results |
---|---|
2019 | 2 |
2022 | 1 |
2023 | 1 |
2024 | 2 |
Search Results
6 results
Results by year
Filters applied: . Clear all
It looks like you are searching for an author.
Results are currently sorted by Best Match. To see the newest results first,
change the sort order to Most Recent.
Page 1
Clinical Efficacy of ONC201 in H3K27M-Mutant Diffuse Midline Gliomas Is Driven by Disruption of Integrated Metabolic and Epigenetic Pathways.
Cancer Discov. 2023 Nov 1;13(11):2370-2393. doi: 10.1158/2159-8290.CD-23-0131.
Cancer Discov. 2023.
PMID: 37584601
Free PMC article.
Phase I dose escalation and expansion trial of single agent ONC201 in pediatric diffuse midline gliomas following radiotherapy.
Gardner SL, Tarapore RS, Allen J, McGovern SL, Zaky W, Odia Y, Daghistani D, Diaz Z, Hall MD, Khatib Z, Koschmann C, Cantor E, Kurokawa R, MacDonald TJ, Aguilera D, Vitanza NA, Mueller S, Kline C, Lu G, Allen JE, Khatua S.
Gardner SL, et al. Among authors: daghistani d.
Neurooncol Adv. 2022 Sep 13;4(1):vdac143. doi: 10.1093/noajnl/vdac143. eCollection 2022 Jan-Dec.
Neurooncol Adv. 2022.
PMID: 36382108
Free PMC article.
Item in Clipboard
Selective DRD2 antagonist and ClpP agonist ONC201 in a recurrent non-midline H3 K27M-mutant glioma cohort.
Odia Y, Hall MD, Cloughesy TF, Wen PY, Arrillaga-Romany I, Daghistani D, Mehta MP, Tarapore RS, Ramage SC, Allen JE.
Odia Y, et al. Among authors: daghistani d.
Neuro Oncol. 2024 May 3;26(Supplement_2):S165-S172. doi: 10.1093/neuonc/noae021.
Neuro Oncol. 2024.
PMID: 38386699
Free PMC article.
Item in Clipboard
Safety and pharmacokinetics of ONC201 (dordaviprone) administered two consecutive days per week in pediatric patients with H3 K27M-mutant glioma.
Odia Y, Koschmann C, Vitanza NA, de Blank P, Aguilera D, Allen J, Daghistani D, Hall M, Khatib Z, Kline C, MacDonald T, Mueller S, Faison SL, Allen JE, Naderer OJ, Ramage SC, Tarapore RS, McGovern SL, Khatua S, Zaky W, Gardner SL.
Odia Y, et al. Among authors: daghistani d.
Neuro Oncol. 2024 May 3;26(Supplement_2):S155-S164. doi: 10.1093/neuonc/noae001.
Neuro Oncol. 2024.
PMID: 38400780
Free PMC article.
Clinical Trial.
Item in Clipboard
Pediatric and adult H3 K27M-mutant diffuse midline glioma treated with the selective DRD2 antagonist ONC201.
Chi AS, Tarapore RS, Hall MD, Shonka N, Gardner S, Umemura Y, Sumrall A, Khatib Z, Mueller S, Kline C, Zaky W, Khatua S, Weathers SP, Odia Y, Niazi TN, Daghistani D, Cherrick I, Korones D, Karajannis MA, Kong XT, Minturn J, Waanders A, Arillaga-Romany I, Batchelor T, Wen PY, Merdinger K, Schalop L, Stogniew M, Allen JE, Oster W, Mehta MP.
Chi AS, et al. Among authors: daghistani d.
J Neurooncol. 2019 Oct;145(1):97-105. doi: 10.1007/s11060-019-03271-3. Epub 2019 Aug 27.
J Neurooncol. 2019.
PMID: 31456142
Free PMC article.
Item in Clipboard
First clinical experience with DRD2/3 antagonist ONC201 in H3 K27M-mutant pediatric diffuse intrinsic pontine glioma: a case report.
Hall MD, Odia Y, Allen JE, Tarapore R, Khatib Z, Niazi TN, Daghistani D, Schalop L, Chi AS, Oster W, Mehta MP.
Hall MD, et al. Among authors: daghistani d.
J Neurosurg Pediatr. 2019 Apr 5;23(6):719-725. doi: 10.3171/2019.2.PEDS18480.
J Neurosurg Pediatr. 2019.
PMID: 30952114
Item in Clipboard
Cite
Cite